TABLE 2.
Cer composition of VitC-supplemented cultured HCFs and HKCs
| HCFs | HKCs | |||||||
| Cer Species | Control | T1 | T2 | T3 | Control | T1 | T2 | T3 |
| C14:0 | 0.21 ± 0.02 | 0.22 ± 0.04 | 0.29 ± 0.06 | 0.31 ± 0.06 | 0.36 ± 0.05 | 0.29 ± 0.02a | 0.35 ± 0.02 | 0.40 ± 0.04 |
| C16:0 | 9.23 ± 0.80 | 6.14 ± 0.42b | 8.43 ± 1.50 | 9.13 ± 1.32 | 11.22 ± 1.08a | 8.75 ± 0.84a,b | 8.89 ± 1.35 | 11.84 ± 1.60 |
| C18:1 | 0.48 ± 0.42 | 0.02 ± 0.03 | 0.38 ± 0.33 | 0.32 ± 0.28 | 0.22 ± 0.39 | 0.00 ± 0.00 | 0.60 ± 0.57 | 0.42 ± 0.36 |
| C18:0 | 1.33 ± 0.42 | 0.96 ± 0.27 | 1.66 ± 0.76 | 1.72 ± 0.19 | 3.13 ± 0.73 | 1.87 ± 0.54 | 3.09 ± 0.59 | 2.56 ± 0.07a |
| C20:0 | 0.45 ± 0.18 | 0.35 ± 0.09b | 0.57 ± 0.16 | 0.58 ± 0.11 | 1.22 ± 0.35a | 0.63 ± 0.17 | 1.12 ± 0.40 | 0.87 ± 0.15a |
| C22:0 | 1.72 ± 0.21 | 1.25 ± 0.15 | 1.91 ± 0.52 | 2.04 ± 0.39 | 3.02 ± 0.14a | 2.07 ± 0.61 | 3.07 ± 0.74 | 2.77 ± 0.36 |
| C24:1 | 4.77 ± 0.59 | 3.40 ± 0.36b | 5.58 ± 0.57 | 5.53 ± 1.13 | 7.23 ± 1.31a | 5.62 ± 0.48a | 5.61 ± 1.11 | 7.99 ± 1.25 |
| C24:0 | 3.17 ± 0.23 | 2.37 ± 0.44 | 3.80 ± 0.69 | 3.45 ± 0.32 | 5.55 ± 1.31a | 4.27 ± 0.35a | 4.81 ± 0.62 | 5.46 ± 0.58a |
| C26:1 | 0.27 ± 0.01 | 0.16 ± 0.02 | 0.21 ± 0.05 | 0.19 ± 0.03 | 0.23 ± 0.07 | 0.19 ± 0.01 | 0.19 ± 0.01 | 0.26 ± 0.05 |
| C26:0 | 0.02 ± 0.01 | 0.01 ± 0.01 | 0.01 ± 0.01 | 0.01 ± 0.01 | 0.02 ± 0.01 | 0.02 ± 0.01 | 0.01 ± 0.01 | 0.02 ± 0.01 |
| Total | 21.63 ± 0.98 | 14.87 ± 1.59b | 22.84 ± 4.44 | 23.27 ± 3.08 | 32.11 ± 1.23a | 23.70 ± 2.02a,b | 27.75 ± 3.10 | 32.59 ± 3.18a |
Both cultures were treated with three isoforms of TGF-β, namely, T1, T2, and T3, as described in the Methods. Individual Cer species were quantitatively determined by UPLC-MS/MS and are presented as picomoles per milligram of cells (mean ± SD; n = 4).
a
Statistically significant difference between HCFs and HKCs (P ≤ 0.01).
b
Indicates statistically significant difference between control and TGF-β-treated cells for both cell types.